New blood test may monitor coeliac disease

Need for endoscopy may be avoided with assay that also detects mucosal healing, researchers say

A new biomarker assay may detect coeliac disease and monitor its progress, new research suggests.

The authors say they have identified immunogenic epitopes of the (tissue transglutaminase-deamidated gliadin-derived peptide (tTG-DGP) complex, and an assay to measure the immune response to epitopes accurately identified patients with coeliac disease, as well as patients with mucosal healing.

Researcher Dr Rok Seon Choung, of Mayo Clinic in Rochester, Minnesota, said the the new serologic biomarker discovered in this study would improve diagnostic accuracy and monitoring of coeliac disease activity.

"Furthermore, utilising this marker may enable patients to avoid unnecessary invasive procedures such as endoscopy with duodenal biopsy," Dr Choung said.

Dr Choung and colleagues analysed serum samples from 90 patients with biopsy-proven coeliac disease and 79 healthy control participants for immune